🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

29 results for “Argenx” Clear

  1. ARGX-113

    Argenx

    Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  2. ARGX-113

    Argenx

    Primary immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  3. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Efgartigimod, Placebo for efgartigimod

    Argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  5. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    Argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  6. PBO PH20 SC, ARGX-113

    Argenx

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  7. PREDNISONE, PREDNISONE, ARGX-113, PREDNISONE, PREDNISONE, PBO PH20 SC

    Argenx

    Bullous Pemphigoid (BP)

    phase 3 small molecule active

    1 trial

  8. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. Placebo for efgartigimod, ARGX-113

    Argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  10. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    Argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  12. Placebo matching IMP., Vyvgart 1 000 mg solution for injection in pre-filled syringe

    Argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  13. Placebo solution for IV infusion, ARGX-117, HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo solution for IV infusion, HUMAN NORMAL IMMUNOGLOBULIN (IV)

    Argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  14. Placebo to ARGX-113 solution for injection, ARGX-113

    Argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

  15. Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    Argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  17. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    Argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  18. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  19. Vyvgart 20 mg/mL concentrate for solution for infusion

    Argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  20. A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS)

    Argenx

    congenital neuromuscular disorders

    phase 2 other active

    1 trial

  21. ARGX-117, ARGX-113

    Argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  22. Efgartigimod, ARGX-113

    Argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  23. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    Argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  24. Placebo to ARGX-117 IV concentrate solution for infusion, ARGX-117

    Argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources